Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BMS-927711 (CGRP Antagonist)
BMS-927711 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1: BMS-927711 (300 mg) | ACTIVE_COMPARATOR | - |
| Arm 2: BMS-927711 (600 mg) | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BMS-927711 (CGRP Antagonist) | DRUG | Capsule, Oral, 300 mg, Once, One day |
Inclusion Criteria: * Patients with migraine with or without aura who are otherwise healthy as determined by medical history, physical examination, clinical laboratory evaluations and 12-lead electrocardiogram (ECG), will be eligible * Men or women \[women of childbearing potential (WOCBP) or Women...
Top 5 of 8 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 13 | PHASE3 | Atogepant, Ubrogepant, MEDI0618 |
| Pfizer Inc. | PFE | 11 | PHASE3 | Rimegepant, Zavegepant |
| Eli Lilly and Company | LLY | 2 | PHASE3 | Galcanezumab |
| Amgen Inc. | AMGN | 2 | PHASE3 | Erenumab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
BMS-927711 is an investigational small molecule being studied for the treatment of migraine. It was evaluated in a Phase 1 clinical trial in patients with migraine. It is not approved for any indication and remains in clinical development.
BMS-927711 is a CGRP antagonist, meaning it targets the calcitonin gene-related peptide pathway. This mechanism is being explored for migraine treatment. The drug is a small molecule developed by Pfizer.
BMS-927711 is being developed by Pfizer, Inc. The company's ticker symbol is PFE. Pfizer is responsible for the clinical development of this investigational migraine therapy.
BMS-927711 is in Phase 1 clinical development. It has completed one Phase 1 trial and has no active trials at this time. The drug is investigational and has not been approved by the FDA.
BMS-927711 has been studied in one completed Phase 1 trial, NCT01445067, titled "Study to Evaluate the PK of BMS-927711 in Patient With Migraine During Acute Migraine and Non-migraine Condition." The trial enrolled 48 patients in the United States and was active-controlled.
Yes, BMS-927711 is also known as BMS-927711 (CGRP Antagonist). The parenthetical name reflects its mechanism as a CGRP antagonist. Both names refer to the same investigational drug for migraine.